Healius (ASX:HLS) Announces Pathology Strategy and $300M Dividend at Investor Day 2025
Healius (ASX:HLS) reveals a new pathology strategy and a $300 million special dividend during Investor Day 2025.
Category: ASX-HLS
Healius
Latest News
Orora Limited (ASX:ORA) Under Review by French Competition Authority
Dreadnought Resources Ltd (ASX:DRE) Successfully Raises $8.5M in Capital Placement
Chariot Corporation Limited (ASX:CC9) Announces Second Amendment to Black Mountain Purchase Option
Renascor Resources Limited (ASX:RNU) Announces Receipt of ECI Submissions for Upstream Graphite Operation
Triangle Energy (ASX:TEG) Revises Sale Terms for Cliff Head Assets
ASF Group Limited (ASX:AFA) Becomes Debt Free
Australian Rare Earths Limited (ASX:AR3) Extends Uranium Mineralisation
Artrya Limited (ASX:AYA) Receives FDA Clearance for Salix® Coronary Anatomy
Avecho Biotechnology Limited (ASX:AVE) Receives US$3M Licensing Fee from Sandoz
The Star Entertainment Group (ASX:SGR) Casino Licence Suspension Extended
Orora Limited (ASX:ORA) Under Review by French Competition Authority
Dreadnought Resources Ltd (ASX:DRE) Successfully Raises $8.5M in Capital Placement
Chariot Corporation Limited (ASX:CC9) Announces Second Amendment to Black Mountain Purchase Option
Renascor Resources Limited (ASX:RNU) Announces Receipt of ECI Submissions for Upstream Graphite Operation
Triangle Energy (ASX:TEG) Revises Sale Terms for Cliff Head Assets
ASF Group Limited (ASX:AFA) Becomes Debt Free
Australian Rare Earths Limited (ASX:AR3) Extends Uranium Mineralisation
Artrya Limited (ASX:AYA) Receives FDA Clearance for Salix® Coronary Anatomy
Avecho Biotechnology Limited (ASX:AVE) Receives US$3M Licensing Fee from Sandoz
The Star Entertainment Group (ASX:SGR) Casino Licence Suspension Extended
The Hub of Australian Finance News